To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Tobira Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
Read time: Less than a minute
Tobira Therapeutics Inc. has announced pharmacokinetic data and results from two Phase I pharmacokinetic studies for TAK-652, an investigational compound being developed for the treatment of HIV.
These data suggest that TAK-652 is rapidly absorbed and demonstrate relatively good oral bioavailability (as shown by the plasma TBR-652 concentration data) and has a long plasma half-life of TBR-652 (approximate mean of 35 hours) supporting once-daily dosing.
Mean TBR-652 plasma concentrations were well above the predicted target plasma concentration (2ng/mL) with or without food. In both studies TBR-652 was safe and well tolerated in this healthy subject population when administered over a dose range of 10 mg to 800 mg in 2 tablet formulations.
"These two Phase I studies provide encouraging support for TAK-652 as a therapeutic option for the treatment of HIV. We look forward to results from our on-going proof-of-concept study," said James Sapirstein, CEO.
These data were presented at the 5th International Conference on HIV Pathogenesis, Treatment and Prevention, held July 19-23, 2009 in Cape Town, South Africa.
These data suggest that TAK-652 is rapidly absorbed and demonstrate relatively good oral bioavailability (as shown by the plasma TBR-652 concentration data) and has a long plasma half-life of TBR-652 (approximate mean of 35 hours) supporting once-daily dosing.
Mean TBR-652 plasma concentrations were well above the predicted target plasma concentration (2ng/mL) with or without food. In both studies TBR-652 was safe and well tolerated in this healthy subject population when administered over a dose range of 10 mg to 800 mg in 2 tablet formulations.
"These two Phase I studies provide encouraging support for TAK-652 as a therapeutic option for the treatment of HIV. We look forward to results from our on-going proof-of-concept study," said James Sapirstein, CEO.
These data were presented at the 5th International Conference on HIV Pathogenesis, Treatment and Prevention, held July 19-23, 2009 in Cape Town, South Africa.
